Paysign (PAYS) delivered another quarter in which patient affordability did the heavy lifting. Third-quarter EPS of $0.11 beat the $0.10 consensus by 10.0% and grew 175.0% year over year. Revenue of $30.8 million topped the $29.03 million consensus by 6.1% and rose 42.6%. Management raised full-year gross margin, net income, GAAP EPS and Adjusted EBITDA guidance for a third straight time. The central tension sits on the other side of the business. A plasma customer is moving 113 centers to a bank-affiliated processor, and the full-year revenue range was only reaffirmed. That implies fourth-quarter sales of roughly $26.9 million to $29.9 million, flat to down from the $30.8 million just reported.
The quality of the beat is high, and mix explains it. Pharma revenue rose 109.8% to $16.62 million, accelerating from 89% growth in the second quarter and 82% in the first. It now accounts for more than half of total revenue. Active programs reached 167, revenue per program climbed about 32% to $99,524, and processed claims rose roughly 55%. Because affordability carries richer margins than plasma processing, gross margin expanded 840 basis points to 64.7%, well above the 61% to 63% management had guided. Operating margin jumped to 23.8% from 7.3%. Adjusted EBITDA more than doubled to $10.98 million, per the reconciliation table; the release text cites $10.95 million in one spot. GAAP EPS growth actually understates operating progress. Pretax income rose from $2.25 million to $8.19 million, but the effective tax rate climbed to 17.8% from 1.4% a year ago, and management points to roughly 21% for the full year.
Plasma is where the story is softening. Segment revenue grew just 7.5%, a sharp deceleration from 21% in the second quarter and 25% in the first. Revenue per center continued to rise, to $8,187 a month from $7,699 last quarter. However, the center count fell to 562 from 595 a year earlier. Gross dollar load volume slipped 1.0% and spend volume fell 1.3%. The 113-center loss is material. Those sites generated $11.3 million of trailing revenue and $5.2 million of gross profit, roughly a fifth of the segment's annualized revenue. Management now expects to exit 2026 with 445 to 450 centers. As recently as the second-quarter call, it had expected a slight increase from 561. The fourth-quarter hit is estimated at $1.5 million of revenue and $0.7 million of gross profit, so the full drag lands in 2027.
The forward catalysts are real but uneven. The affordability pipeline is now quantified: 190 to 195 programs at year-end, implying 59 to 64 net adds versus 55 in 2025. New products are slated to be unveiled for 2027. The CFO said the plasma loss does not change the 2027 affordability trajectory. Management also cited talks with a couple of prospective plasma clients to backfill the lost centers. The Aferion donor-management software is the weaker link. In March, management expected regulatory feedback within about 60 days. It now offers no timeline and would not say how many rounds of questions it has faced. Bears have legitimate ammunition on two fronts: an opaque FDA process, and bank-partner consolidation that could strike plasma again. Tone stayed confident on pharma but turned noticeably more defensive on plasma and Aferion.
The market setup is more complicated than the surprise implies. Shares closed at $14.69 heading into the report, up 41.8% from the open after the August release. They sat 71.5% above the 200-day moving average of $8.57 and about 9.1% below the $16.15 52-week high set on October 20. Despite that run, Earnings Whispers investor sentiment remained negative and weakened modestly, moving from -0.12 to -0.18. Investors have been rewarding the margin story while staying wary. The Earnings Whispers note that the raise brings guidance closer to estimates suggests the Street had already been modeling profitability above management's prior range. That limits how much of the upgrade is truly new. Most directional trend readings remain positive, consistent with the stock's strong run.
The bottom line is that Paysign's earnings engine is changing faster than its revenue line shows. Pharma growth is accelerating, margins are structurally higher, the balance sheet holds $34.5 million of unrestricted cash and no bank debt, and profit guidance keeps rising. But the quarter also exposed the concentration risk in plasma, a sequential revenue air pocket in the fourth quarter, and a stalled software catalyst. With the stock already near its highs, the next leg depends on affordability growth outrunning the plasma shortfall in 2027 rather than merely offsetting it.